Category Archives: Why It Works

Diabetes, Immunotherapy, News, Science

Immune System Genes Show Links to Type 1 Diabetes – By Serena Gordon, HealthDay Reporter

WEDNESDAY, Sept. 8 (HealthDay News) — The exact cause of type 1 diabetes is still unknown, but international researchers have found a link between the blood sugar disorder and a network of immune system genes.

Using a genome-wide association study, the researchers found that a certain group of genes that react in response to viral infections were present in both rats and humans, and that those same genes were also associated with a susceptibility to type 1 diabetes.

“Diseases arise as a result of many genetic and environmental factors through gene networks that cause tissue damage,” explained study senior author Dr. Stuart Cook, the group head of molecular and cellular cardiology at the Medical Research Council Clinical Sciences Centre, and a professor of clinical and molecular cardiology at Imperial College in London.

“We used an approach to identify the major control points’ central command of an inflammatory gene network. This led us to uncover hundreds of new genes that might cause diabetes and one major control gene that controls the whole network,” said Cook.

He added that one of the genes belongs to a class of genes that might make a good target for drug therapy in the future.

Results of the study are published in the Sept. 9 issue of Nature.

Each year, more than 30,000 people are diagnosed with type 1 diabetes, formerly known as juvenile diabetes, according to the Juvenile Diabetes Research Foundation (JDRF). People with type 1 diabetes no longer produce enough of the hormone insulin to effectively use the sugars found in carbohydrate-containing foods. To survive, people with type 1 diabetes must take insulin injections or use an insulin pump for the rest of their lives.

Experts believe the disease is an autoimmune disease, which means that the body’s immune system mistakenly turns against healthy cells, such as the insulin-producing cells in the pancreas, and destroys them. People who develop type 1 diabetes are believed to have a genetic susceptibility to the disease that’s then triggered by something in the environment, possibly a virus.

In the current study, the researchers didn’t initially set out to look for type 1 diabetes genes. They started out by looking at a certain group of genes in rats, in this case a network of genes controlled by a gene called interferon regulatory factor 7 (IRF7). IRF7 is like a master switch that controls the genes in its network. The entire network of genes controlled by IRF7 is called the IRF7-driven inflammatory network (IDIN).

The researchers discovered that when there were differences in IRF7, there were also differences in the way other genes expressed themselves.

Cook and his colleagues then searched for a network of genes in humans that might behave the same way. They found an area on chromosome 13q32 that is controlled by a gene called the “Epstein-Barr virus induced gene 2” (Ebi2). This gene appeared to be the human equivalent of the IRF7 gene in rats.

Within this human version of the IDIN, research found a gene called IFIH1, which has been found in other research to be associated with the development of type 1 diabetes.

“Usually, research starts from the genetics and goes to function. Here, they started with a function — [an immune system reaction] — and were looking for a gene,” explained Marie Nierras, director of research and scientific affairs for the JDRF.

“The value of such a result is that if you can get to the same place using more than one pathway, it tends to support the hypothesis,” she said.

In this case, the hypothesis supported is the idea that type 1 diabetes may be triggered by an immune system response to a virus. However, Nierras stressed that this study doesn’t conclusively prove that a virus is the trigger for type 1 diabetes.

“We know better today that this network of genes is involved, and with a network, you have many targets you can test. This research invites us to plan experiments going forward, and opens up many more questions, like ‘If I disrupt this branch of the network, do I disrupt diabetes?’ Or, ‘If you look back at previous research knowing this study’s results, does that help to better explain previous results?'” said Nierras.

Cook said this type of genome-wide association study can be used for other diseases as well, and that his team is hoping to eventually develop a new drug based on the genetic target they discovered.

More information

Learn more about type 1 diabetes and its causes from the U.S. National Library of Medicine.

SOURCES: Stuart Cook, M.D., Ph.D., group head, molecular and cellular cardiology, the Medical Research Council Clinical Sciences Centre, and professor, clinical and molecular cardiology, Imperial College, London; Marie Nierras, Ph.D., director, research and scientific affairs, Juvenile Diabetes Research Foundation, New York City; Sept. 9, 2010, Nature

Copyright © 2010 HealthDay. All rights reserved.

 http://www.businessweek.com/lifestyle/content/healthday/642915.html

Cancer, Immunotherapy, Medical Studies, PSK

Protein-bound polysaccharide-K (PSK) directly enhanced IgM production in the human B cell line BALL-1

Maruyama S, Akasaka T, Yamada K, Tachibana H.

Laboratory of Food Chemistry, Division of Applied Biological Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Higashi-ku, Fukuoka, Japan. marushins2003@ybb.ne.jp

Abstract

Protein-bound polysaccharide-K (PSK) prepared from the basidiomycete Coriolus versicolor has been used as a biological response modifier for the treatment of cancer patients. Many studies describing the immunomodulatory effects and direct anti-cancer effects of PSK have been reported. Most of studies describing the immunomodulatory effects focused on cellular immunity, although there were several studies which focused on humoral immunity where PSK was shown to be able to induce antibody production in vivo. However, even in these humoral immunity studies, it is thought that the enhancement of antibody production was due to the activation of cellular immunity. In this study, we investigated the direct effect of PSK on B cells and discovered that PSK was able to enhance IgM production in the human B cell line BALL-1. Furthermore, BALL-1 was shown to have the characteristic features of B-1a cells, which are independently involved in the primary immune response. These results show that there is a possibility that PSK directly acts on B cells and simultaneously enhances both humoral immunity and cellular immunity.

PMID: 18848763 [PubMed – indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/pubmed/18848763

Immunotherapy, Medical Studies, PSP

Immunomodulatory effects of polysaccharopeptide (PSP) in human PBMC through regulation of TRAF6/TLR immunosignal-transduction pathways.

Li W, Liu M, Lai S, Xu C, Lu F, Xiao X, Bao Y.

Department of Clinical Laboratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Abstract

Context: Polysaccharopeptide (PSP) was extracted from Coriolus versicolor, and has been proved to be a valuable adjuvant for the combination with chemotherapy or radiotherapy in the treatment of various cancers. Objective: To understand the mechanism of PSP on immunomodulation, we examined gene expression and cytokine secretion associated with immunosignal-transduction signaling in human peripheral blood mononuclear cells (PBMCs). Methods: cDNA microarray and cytokine antibody array were used to identify differential gene expression profiles and cytokines secretion of PBMCs in the presence or absence of PSP for 24 h. The expression of the key genes and proteins related to Toll-like receptor (TLR) signaling and its downstream pathway was determined by RT-PCR or Western blot. Results: Compared with the control group, PSP up-regulated 22 genes expression (such as IFN-gamma, CXCL10, TLR4, TLR5) in 117 genes associated with TLR signaling. Twenty-three of genes (e.g., TLR9, TLR10, SARM1, TOLLIP) related with TLR signaling pathway were down-regulated in PBMCs under PSP treatments. Five of cytokines (GCSF, GM-CSF, IL-1alpha, IL-6, IFN-gamma) were up-regulated more than 1.3 times by PSP. The mRNA levels of TRAM, TRIF, and TRAF6, which are the key molecules of TLR signaling pathway, were markedly increased (P < 0.05). Moreover, the protein level of TRAF6 was also markedly increased (P < 0.01). Conclusions: PSP-regulated gene expression and cytokine secretion related to TLR signaling pathway in human PBMCs. Especially, TRAM-TRIF-TRAF6 subsignaling pathway of TLR may be one of the key associated signaling pathways in the immunomodulation of PSP.

PMID: 20131955 [PubMed – as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/20131955

Cancer, Immunotherapy, Interleukin, Medical Studies

Antimetastatic and immunomodulating effect of water extracts from various mushrooms.

Han SS, Cho CK, Lee YW, Yoo HS.

East-West Cancer Center, College of Oriental Medicine, Daejeon University, Daejeon, Korea.

Abstract

This experiment was conducted to evaluate inhibitory effects against lung metastasis and promotion of splenocytes by water extracts from various mushrooms including Armillaria mellea, Grifola frondosa, Garnoderma frondosa, Codyceps militaris, Hericium erinaceus, Coriolus versicolor, Agaricus Blazei with Lycium Chinense Miller (known as M8). Analysis of carbohydrate using HPTLC showed that beta-glucan and pachyman were some of the major components of M8. Oral administration of M8 resulted in a dose-dependent tendency to inhibit lung metastasis after intravenous injection of colon26-L5 cells. Treatment with M8 resulted in a significant increase of T cell and B cell mitogenic stimuli. The population of CD3, CD19, CD4, and CD8 positive cells increased in a dose dependent manner of M8 administration. However, no significant results were obtained from the population of Mac-1 and NK1.1 positive cells. Oral administration of M8 resulted in the increased production of IFN-gamma and IL-4 by splenocytes stimulated with Con A compared with untreated controls. These results show that M8 has antitumor activities which may be useful as an antimetastatic agent.

PMID: 20633495 [PubMed – in process]

http://www.ncbi.nlm.nih.gov/pubmed/20663037

Autoimmune Disease, Lymphocytes, Medical Studies, PSP

Regulatory properties of polysaccharopeptide derived from Coriolus versicolor and its combined effect with ciclosporin on the homeostasis of human lymphocytes.

Lee CL, Jiang P, Sit WH, Yang X, Wan JM.

School of Biological Sciences, Kadoorie Biological Sciences Building, The University of Hong Kong, Pokfulam Road, Hong Kong SAR.

Abstract

OBJECTIVES: Lymphocyte homoeostasis is essential in inflammatory and autoimmune diseases. In search of natural fungal metabolites with effects on lymphocyte homoeostasis, we recently reported that polysaccharopeptide (PSP) from Coriolus versicolor exhibited ciclosporin-like activity in controlling aberrant lymphocyte activation. This object of this study was to investigate its effect on lymphocyte homoeostasis. This was done by investigating the mechanistic actions of PSP in relation to ciclosporin by performing cell cycle and cell death analysis of human lymphocytes in vitro.

METHODS: We investigated the effect of PSP in the presence and absence of ciclosporin on cell proliferation, cell cycle, cell death, immunophenotype and cell cycle regulatory proteins in human lymphocytes.

KEY FINDINGS: The data showed that PSP exhibited homoeostatic activity by promoting and inhibiting the proliferation of resting and phytohaemagglutinin (PHA)-stimulated lymphocytes, respectively. PHA-stimulated lymphocytes exhibited G0/G1 cell cycle arrest that was accompanied by a reduction of cyclin E expression with PSP treatment. Both PSP and ciclosporin blocked the reduction of the CD4/CD8 ratio in stimulated lymphocytes. PSP did not induce cell death in human lymphocytes, but the suppression of the Fasreceptor suggested a protective role of PSP against extrinsic cell death signals. These homoeostatic effects were more potent with combined PSP and ciclosporin treatment than with either fungal metabolite alone.

CONCLUSIONS: Collectively, the results reveal certain novel effects of PSP in lymphocyte homoeostasis and suggest potential as a specific immunomodulatory adjuvant for clinical applications in the treatment of autoimmune diseases.

PMID: 20663037 [PubMed – in process]

http://www.ncbi.nlm.nih.gov/pubmed/20663037

Cancer, Clinical Trials, Gastric Cancer, Immunotherapy, Medical Studies, PSK

Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection.

A total of 103 patients with advanced gastric carcinoma were randomized after curative surgery to receive an alternate administration of carbazilquinone (CQ) and PSK (Krestin) or carbazilquinone alone. Each course of therapies started 1 week after the surgical operation and therapy schedules consisted of 9 courses. In each course of 6 weeks, CQ (2 mg/m2/week) was administered on day 0, 8, and 15. In combined immunochemotherapy group, PSK was given orally in 3-divided doses of 2 g/m2/day from the day of the third CQ administration for consecutive 4 weeks. Estimated survival rate and cumulative survival curve were compared utilizing the data up to 7 years after the operation. There was no overall significant difference in survival rates between the CQ plus PSK group and the CQ alone group, but a group of patients whose disease was classified as S1 + S2(N1-2) survived significantly longer when treated with the combination of CQ and PSK. Neither in more advanced cases (greater than S3 or greater than N3) nor in cancers of early stages, the addition of PSK provided an additive effect. The favorable result obtained in one subgroup treated with PSK, suggests that the use of this agent in treating gastric cancers should be carefully evaluated in terms of serosal infiltration and nodal metastasis.

Clinical Trials, Colorectal Cancer, Immunotherapy, Medical Studies, PSK

Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.

PURPOSE: Intravenous fluorouracil and leucovorin for six to eight months is currently a standard adjuvant treatment for Stage III colon cancer; however, this regimen is complex, inconvenient, and has a high intolerability. Adjuvant chemotherapies are claimed for objective response rates with an acceptable safety profile and complexity. We investigated the benefits of oral protein-bound polysaccharide K added to oral tegafur/uracil on curatively resected Stage II or III colorectal cancer. METHODS: We prospectively randomized 207 patients to treatments of either oral 3.0 g protein-bound polysaccharide K plus 300 mg tegafur/uracil or 300 mg tegafur/uracil alone for two years following 12 mg/m2 and 8 mg/m2 mitomycin treatment on postoperative Days 1 and 2, respectively. The primary end points were disease-free and overall survival, and recurrence rates. RESULTS: Three (1.4 percent) patients were declared ineligible, and three patients did not start treatment. In total, 201 patients were analyzed. The three-year, disease-free survival rate was 80.6 percent (standard error = 3.4 percent) in the protein-bound polysaccharide K group (P = 0.02) compared with 68.7 percent (SE = 5.7 percent) in the control group after a median follow-up of 3.7 years. The estimated relative risk of recurrence in the control group was 1.87 (95 percent confidence interval, 1.10-3.20) at three years. The three-year, overall survival rate was 87.3 percent (standard error = 2.9 percent) in the protein-bound polysaccharide K group and 80.6 percent (standard error = 4.8 percent) in the control group (P = 0.24). The three-year, overall survival rate in 80 pathological TNM Stage III patients was 83.0 percent (standard error = 5.2 percent) in the protein-bound polysaccharide K group and 59.3 percent (standard error = 9.5 percent) in the control group (P = 0.02). Protein-bound polysaccharide K prevented distant metastases (P = 0.05), particularly lung metastases (P = 0.01). The incidence of adverse effects was minimal, and compliance was good. CONCLUSION: Adjuvant therapy using a combination of oral protein-bound polysaccharide K and tegafur/uracil is highly effective in preventing the recurrence of colorectal cancer in Stage II or III patients, and increases overall survival in pathological TNM Stage III. These results will be a sufficient proof to conduct a larger study to compare tegafur/uracil/protein-bound polysaccharide K with 5-fluorouracil/leucovorin.

Immunotherapy, News, PSK, PSP

Introducing inForce Immune Builder

Irvine, California (September 7, 2010) inLife, LLC, distributors of science-based Health & Wellness products, today introduced inForce Immune Builder, a new product that clinical research shows helps stimulate the body’s immune system. inForce’s main ingredient, the Coriolus versicolor mushroom mycelia extract, is one of the most widely studied supplements for its immune building properties and is now available to the public and the direct-selling industry. Worldwide, there have been over 400 animal and human studies on Coriolus versicolor, with over a dozen placebo-based human trials conducted in the west.

inLife Immune Builder with PSP and PSK
inLife offers Coriolus versicolor as a Daily Dietary Supplement in vegan capsule form to help maintain and stimulate the body’s immune system. Coriolus versicolor, PSK and PSP are among the most widely studied supplements for their immune building properties. One would be hard pressed to find another immune boosting product that has had more research completed or positive comments associated with it. The amount of worldwide comments and studies is compelling. inForce Immune Builder is a proprietary blend of both Polysaccharide-K (PSK) and Polysaccharide Peptide (PSP). Both offer much-needed immune building assistance and they can be taken on a daily basis. The products are bottled in the United States in an FDA-registered bottling facility that is cGMP compliant (Current Good Manufacturing Practices).

Hospital and Research Institutes Report on Coriolus Versicolor
In the United States, top-ranked hospital and research institutes have reported that “Coriolus versicolor, PSK and PSP help boost the body’s immune system with limited side effects and safety of daily oral doses for extended periods of time.” In addition, Coriolus versicolor and its potential positive effects has been studied very closely by M.D. Anderson, University of Texas, Loma Linda University, Beth Israel Deaconess Medical Center (a teaching hospital of Harvard Medical School) , The University of San Diego, Sloan-Kettering Center (New York), and Bastyr University (Kenmore, Washington), just to name a few.

About inLife, LLC
Founded in 2007, inLife has been very successful in bringing to the market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain. For more information on inForce Immune Builder and the company, please review www.myinlife.com. For further details on inForce, journalists may contact Thomas Kiklas directly at 949-648-2525.

# # #

Founded in 2007, inLife has been very successful in bringing to the market products that have efficacies that are soundly based on scientific research. inLife products are now available in the U.S. as well as the U.K, Canada and Spain.

Click here to download this press release.

Autoimmune Disease, Chronic Fatigue Syndrome, Clinical Trials, Fibromyalgia, Medical Studies, Preventative

Mushroom immunutrition in Chronic Fatigue Immune Dysfunction Syndrome

In the recently published edition of the Journal of Integrated Medicine (Online version), Dr. Jean Monro of the Breakspear Hospital outlines the impact of Coriolus versicolor supplementation as immunonutrition in thirty-six (36) Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) patients over a six week period.

The 36 patients were selected on the basis of international criteria for the diagnosis of CFIDS. Ages ranged from 17 years to 83 years and there was a female-to-male ratio of 2:1. In addition, the patients had a combination of high antibody levels to Epstein Barr virus (EBV) and/or Herpes Simplex 6 virus (HHV6) and/or Cytomegalovirus. (CMV).

Patients were given Coriolus versicolor (non-extracted) 6 tablets daily for 15 days (3 g/day), followed by 3 tablets daily for 45 days (1.5 g/day). Immune parameters were measured before and after the sixty (60) day supplementation period.

Results were noted in two areas:

1) Natural Killer Cells–before treatment the average NK cell level was average=129.64/mm3. After treatment this had increased to 175/mm3, an increase of 35%.

2) T cells (CD3 CD26)–there was increased activation in 66% of patients and T cell depression in 22% of patients. T cell level was unchanged in 11% of the patients.

Conclusion

Supplementation with non-extracted Coriolus versicolor showed improvements in both immune parameters and viral levels in the majority of the thirty-six (36) CFIDS patients, indicating that Coriolus versicolor supplementation has the potential to play a significant role in the treatment of CFIDS.

Breast Cancer, Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Human Papillomavirus (HPV), Immunotherapy, Lung Cancer, Lymphocytes, Medical Studies, News, PSK, PSP

Coriolus Versicolor is Potent Mushroom for Fighting Cancer and Autoimmune Diseases – By: Barbara L. Minton, citizen journalist

(NaturalNews – January 28, 2009) For thousands of years Chinese medicine has prized the mushroom for its energizing and healing properties. Chinese legend is filled with stories of those who discovered the 1,000 year old mushroom and became immortal. In the West, acceptance is based less on tradition and more on the results of the scientific method. Researchers have been busy scientifically documenting what Chinese tradition dictates, that mushrooms are some of the most potent medicines on the plant. Recent research findings have shown the Coriolus versicolor mushroom stands out above the rest for regulating the immune system.

Coriolus versicolor found to be effective against cancer and human papillomavirus

Researchers at the Sloan-Kettering Cancer Center in New York tested several botanicals for their immune enhancing activity using a subcutaneous immunization model of cell surface carbohydrate expression in cancer cells in a study published in September, 2008 Vaccine. They found Coriolus versicolor to display consistent and significant immune enhancement activity superior to all other coumpounds tested. The superiority of Coriolus to yeast beta-glucan, maitake, turmeric, echinacea, and preparation H-48 from Honso USA, was described as surprising. Although the exhibited levels of immune enhancing ability of astragalus was also impressive, it was surpassed by that of Coriolus.

The March, 2008 BMC Cancer reports Coriolus versicolor has shown anticancer activity with positive results in the treatment of gastric, esophageal, colorectal, breast and lung cancers. The efficacy of its protein-bound polysaccharide as an immunomodulator is credited. This activity was independent of its previously described immunomodulatory effect on NK cells.

The journal Cancer Immunology and Immunotherapy reports double blind trials on 111 patients with colorectal cancer, using Coriolus versicolor. Although traditional medicine offers little help for colon cancer patients, Coriolus showed a remarkable enhancement of the patient’s white blood cells, even in advanced colon cancer cases. The white cells greatly increased natural chemotactic motion and phagocytosis, the ability to scavenge toxins and kill pathogens. Coriolus was also used with patients as a helpful maintenance therapy following cancer surgery.

The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) were so impressive they were presented in 2008 at the 20th European Congress of Obstetrics and Gynocology. Dr. Silva Couto and his research team found that Coriolus versicolor supplementation over the period of one year substantially increased regression of dysplasia and induced clearance of the high-risk subtypes of the HPV responsible for cervical cancer. Coriolus supplementation demonstrated a 72 percent regression rate in lesions compared to 47.5 percent without supplementation, and a 90 percent regression rate in the high risk HPV virus sub-types compared to 8.5 percent without.

After using the supplement for one year, 72.5 percent of recipients reverted to normal cytology compared with only 47.5 percent of the control group. Coriolus supplementation produced a 90 percent regression rate in the high risk HPV virus sub-tupes compared to an 8.5 percent regression without supplementation.

It is also likely that Coriolus versicolor would be beneficial in high-grade squamous intraepithelial lesion (HSIL), a precancerous condition in which the cells of the uterine cervix are moderately or severely abnormal. The lead physician of the study noted that the optimal supplementation period may be as short as six months.

Coriolus versicolor modulates autoimmune diseases

T cells belong to a group of while blood cells known as lymphocytes, and play a central role in cell-mediated immunity. The activation of T helper (Th) cell subsets also plays an important role in immunity. Uncontrolled Th responses lead to autoimmune and inflammatory diseases. The identification of agents that modulate these helper cells is essential for controlling autoimmune diseases. A study from the November, 2008 Journal of Pharmacy and Pharmacology, reported that polysaccharopeptide (PSP) from Coriolus versicolor exhibited the ability to control aberrant T lymphocyte activation through ciclosporin-like activity. PSP alone suppress production of activated T cells.

What makes Coriolus versicolor special?

Coriolus versicolor, also referred to as the turkey-tail mushroom, contains large quantities of Beta-glucans that act to stimulate the immune system. Coriolus can dramatically regenerate and rejuvenate the body. Its most active medicinal components are biological response modifiers called protein-bound polysaccharides. These polysaccharides are known as Krestin or PSK in Japan, and as Yun zhi, or PSP in China. There have been reports of cases of Bell’s palsy clearing up with use of Coriolus for just a few days. Others have found it effective against bronchitis.

Other studies have shown that Coriolus can double the number of natural killer cells after only 8 weeks of treatment. Coriolus has also been found to help patients with chronic fatigue syndrome and may be an effective treatment for Lyme disease.

More research documents the anti-tumor benefits of Coriolus

Japanese researchers screened 200 of the best phytochemicals (plant extracts) known for anti-tumor activity. Coriolus versicolor was designated as exhibiting the greatest amount of anti-tumor activity. In another Japanese study, 185 people with lung cancer at different stages were given radiation. Doctors found those who also took Coriolus showed the best tumor shrinkage and the best survival rate. Another study involving stomach cancer patients produced similar results. Those who received Coriolus survived significantly longer, felt better and had fewer side effects.

Coriolus is first line defense against infection

Coriolus is a good centerpiece for your natural medicine chest, even if you are currently the picture of health. When any type of infection strikes, you will be ready. Coriolus can be used to target any infected organ, gland or tissue. Its immune enhancing properties provide an increased response to deal effectively with infections, and do this without over stimulating the immune system.

Sources:

Clinical Trial Results Show Proof of Concept for Use of Coriolus Versicolor As Immunonutrition in IPV Patients With Cervical Lesions, Medical News Today.

Coriolus, www.cocoonnutrition.org.

Coriolus Versicolor, University of California, San Diego Complementary and Alternative Therapies for Cancer Patients.

About the author

Barbara is a school psychologist, a published author in the area of personal finance, a breast cancer survivor using “alternative” treatments, a born existentialist, and a student of nature and all things natural.

Source: NaturalNews – http://www.naturalnews.com/025455.html